Publications by authors named "S Gustavsen"
Background: The measurement of neurofilament light (NFL) in blood samples has been established as a sensitive measure of neuroaxonal damage in a wide range of diseases in the peripheral and central nervous system, including multiple sclerosis (MS). Previous studies have identified confounding factors that may influence the serum concentration of NFL.
Aim: We aimed at investigating the relationship between known confounders (age, body mass index, blood volume) and risk factors for MS (smoking and human leukocyte antigen (HLA)) on serum concentrations of NFL in control subjects.
Background/objectives: Gestational diabetes is associated with an increased risk of future type 2 diabetes and cardiovascular disease, but healthy lifestyle changes can prevent the development of these diseases. This study aimed to identify factors that can improve intervention programmes and postpartum support after gestational diabetes.
Methods: Twenty-two women who had experienced gestational diabetes in Norway participated in in-depth interviews following a six-month intervention programme focusing on healthy lifestyle changes.
Introduction: Cannabinoids are approved for spasticity and pain in multiple sclerosis (MS). In 2017 the prevalence of current users in the Italian general population was 10.2%, while data on Italian MS patients are limited.
View Article and Find Full Text PDFArticle Synopsis
- The study explores the pharmacokinetics (how the drug moves in the body) and pharmacodynamics (the effects of the drug) of cannabis-based medicine (CBM) in patients with multiple sclerosis (MS) suffering from neuropathic pain and spasticity.
- Out of 134 participants in a larger trial, 23 were focused on in this substudy, receiving either THC, CBD, a combination, or a placebo, with significant variability in dosages and individual responses observed.
- Though the pharmacokinetic data was similar to previous findings in healthy individuals, no significant effects on the pain and spasticity parameters were noted, although adverse events were more common in the treatment groups compared to placebo.